Availability and prioritisation of COVID-19 vaccines among patients with advanced chronic kidney disease and kidney failure during the height of the pandemic: a global survey by the International Society of Nephrology.

Autor:	Wijewickrama ES; Faculty of Medicine, University of Colombo, Colombo, Sri Lanka., Abdul Hafidz MI; Nephrology Unit, Universiti Teknologi MARA (UiTM), Selangor, Malaysia., Robinson BM; University of Michigan, Ann Arbor, Michigan, USA., Johnson DW; Department of Kidney and Transplant Services, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia., Liew A; Mount Elizabeth Novena Hospital, Singapore., Dreyer G; Renal Medicine, Barts Health NHS Trust, London, UK., Caskey FJ; Population Health Sciences, University of Bristol, Bristol, UK., Bello AK; Nephrology, University of Alberta, Edmonton, Alberta, Canada., Zaidi D; Medicine, University of Alberta, Edmonton, Alberta, Canada., Damster S; International Society of Nephrology, Brussels, Belgium., Salaro S; International Society of Nephrology, Brussels, Belgium., Luyckx VA; Nephrology, University Children's Hospital, Zurich, Switzerland.; Department of Paediatrics and Child Heath, University of Cape Town, Cape Town, South Africa.; Renal Division, Brigham and Women's Hospital, Harvard medical School, Boston, MA, USA., Bajpai D; Nephrology, Seth GS Medical College and KEM Hospital, Mumbai, Maharashtra, India divyaa24@gmail.com.
Jazyk:	angličtina
Zdroj:	BMJ open [BMJ Open] 2022 Dec 30; Vol. 12 (12), pp. e065112. Date of Electronic Publication: 2022 Dec 30.
DOI:	10.1136/bmjopen-2022-065112
Abstrakt:	Objective: Patients with advanced chronic kidney disease (CKD) or kidney failure receiving replacement therapy (KFRT) are highly vulnerable to COVID-19 infection, morbidity and mortality. Vaccination is effective, but access differs around the world. We aimed to ascertain the availability, readiness and prioritisation of COVID-19 vaccines for this group of patients globally. Setting and Participants: Collaborators from the International Society of Nephrology (ISN), Dialysis Outcomes and Practice Patterns Study and ISN-Global Kidney Health Atlas developed an online survey that was administered electronically to key nephrology leaders in 174 countries between 2 July and 4 August 2021. Results: Survey responses were received from 99 of 174 countries from all 10 ISN regions, among which 88/174 (50%) were complete. At least one vaccine was available in 96/99 (97%) countries. In 71% of the countries surveyed, patients on dialysis were prioritised for vaccination, followed by patients living with a kidney transplant (KT) (62%) and stage 4/5 CKD (51%). Healthcare workers were the most common high priority group for vaccination. At least 50% of patients receiving in-centre haemodialysis, peritoneal dialysis or KT were estimated to have completed vaccination at the time of the survey in 55%, 64% and 51% of countries, respectively. At least 50% of patients in all three patient groups had been vaccinated in >70% of high-income countries and in 100% of respondent countries in Western Europe.The most common barriers to vaccination of patients were vaccine hesitancy (74%), vaccine shortages (61%) and mass vaccine distribution challenges (48%). These were reported more in low-income and lower middle-income countries compared with high-income countries. Conclusion: Patients with advanced CKD or KFRT were prioritised in COVID-19 vaccination in most countries. Multiple barriers led to substantial variability in the successful achievement of COVID-19 vaccination across the world, with high-income countries achieving the most access and success. Competing Interests: Competing interests: EW, MIAH, AL, GD, FC, AKB, SD, SS, DZ, VAL and DB have no disclosures. Global support for the ongoing DOPPS programme is provided without restriction on publications by a variety of funders. For details see, https://www.dopps.org/AboutUs/Support.aspx. BMR has received consultancy fees or travel reimbursement since 2019 from AstraZeneca, GlaxoSmithKline and Kyowa Kirin Co, all paid directly to his institution of employment. DJ has received consultancy fees, research grants, speaker’s honoraria and travel sponsorships from Baxter Healthcare and Fresenius Medical Care, consultancy fees from AstraZeneca, Bayer and AWAK, speaker’s honoraria from Ono and BI & Lilly, and travel sponsorships from Ono and Amgen. He is a current recipient of an Australian National Health and Medical Research Council Leadership Investigator Grant. (© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu